Related Experiment Video
Updated: May 27, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease
Ihosvany Fernández Bello1, María T Álvarez, Francisco J López-Longo
1Hematology Unit, Hospital Universitario La Paz-IdiPaz, Madrid, Spain.
Insights
Platelets release soluble CD40L (sCD40L), a key inflammatory mediator, which is elevated in Behçet disease (BD). Platelet matrix metalloproteinase-9 (MMP-9) drives sCD40L shedding and is upregulated by sCD40L, forming a positive feedback loop in BD inflammation.
Area of Science:
- Immunology
- Inflammation Biology
- Vascular Biology
Background:
- Platelets are a primary source of soluble CD40L (sCD40L), a critical inflammatory mediator.
- Behçet disease (BD) is an autoinflammatory vasculitis with unclear pathogenesis.
- Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, are implicated in inflammatory processes.
Purpose of the Study:
- To investigate the role of platelet-derived sCD40L in Behçet disease (BD).
- To explore the influence of platelet MMP-2 and MMP-9 on CD40L shedding.
- To elucidate the potential feedback mechanism between sCD40L and MMP-9 in BD.
Main Methods:
- Flow cytometry and aggregometry assessed platelet activation and aggregates.
- ELISA measured plasma sCD40L, while Western blot analyzed cellular CD40L/CD40.
- Gelatin zymography determined MMP activity; cultured MEG-01 cells studied sCD40L effects on MMP-9 expression.
Main Results:
- BD patients exhibited higher plasma and platelet sCD40L levels compared to controls.
- Elevated plasma and platelet MMP-9 levels were observed in BD patients; MMP-2 levels were unchanged.
- Recombinant sCD40L treatment increased MMP-9 expression in MEG-01 cells, suggesting a feedback loop.
Conclusions:
- Platelet MMP-9 mediates the shedding of sCD40L, contributing to elevated levels in BD.
- sCD40L upregulates MMP-9 expression in megakaryocytes, establishing a positive feedback loop.
- This sCD40L-MMP-9 axis may drive the chronic inflammation characteristic of Behçet disease.
Abstract:
Platelets are the major source of plasma-soluble CD40L (sCD40L), an important inflammatory mediator. This study explored the impact of platelet-derived sCD40L on Behçet disease (BD), an autoinflammatory vasculitis. We also searched for influences by platelet matrix metalloproteinases (MMP) -2 and MMP-9, implicated in several inflammatory diseases, on CD40L shedding from platelet membrane. Platelet activation were studied by flow cytometry and aggregometry, surface expression of CD40L and platelet-leukocyte aggregates by flow cytometry, sCD40L by ELISA, cellular CD40L and CD40 levels by Western blot and MMPs activity by gelatin zymography. The effect of sCD40L on MMP9 expression was studied in cultured MEG-01 cells. Plasma and platelet-released sCD40L levels were higher in BD patients. No differences in platelet activation and in platelet-leukocyte aggregates formation were observed between BD patients and controls. Plasma and platelet MMP-9 levels were increased in BD patients, whereas there was no difference in platelet MMP-2 activity. Since a correlation between plasma sCD40L and platelet MMP-9 activity was observed, we studied the influence of sCD40L on MMP-9 levels in the megakaryoblastic cell line MEG-01. Treatment of MEG-01 cells with recombinant sCD40L increased MMP-9 but did not change MMP-2 levels. In conclusion, sCD40L release from platelets was mediated by MMP-9, and MMP-9 expression was in turn upregulated by sCD40L in the MEG-01 cell line. We conclude that platelets and megakaryocytes might participate in a positive feedback loop occurring between sCD40L and MMP-9 which would contribute to the proinflammatory state observed in BD.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
